Rong Yu, Teng Yuanyin, Zhou Xiaoying
The First Clinical Medical College, Nanjing Medical University, Nanjing, China.
The Second Clinical Medical College, Nanjing Medical University, Nanjing, China.
Cancer Med. 2025 May;14(10):e70948. doi: 10.1002/cam4.70948.
Gastric cancer is one of the most prevalent malignancies of the digestive system and is associated with a poor prognosis, particularly in advanced metastatic stages, where the 5-year survival rate is significantly low.
Recent research has demonstrated that metabolic reprogramming-including alterations in glucose, lipid, and amino-acid metabolism-plays a critical role in both the development and progression of this disease. To gain deeper insights into these metabolic shifts, scientists have increasingly employed metabolomics, a non-invasive technique that detects and quantifies small molecules within cancerous tissues, thereby enhancing prognostic assessments.
Analyzing the metabolic profiles of gastric-cancer tissues can reveal significant changes in key metabolic pathways, which may open new avenues for targeted therapies and ultimately improve patient outcomes.
This article reviews recent advancements in the study of metabolic reprogramming in gastric cancer, aiming to identify potential therapeutic targets and offer new hope to patients.
胃癌是消化系统最常见的恶性肿瘤之一，预后较差，尤其是在晚期转移阶段，5年生存率极低。
最近的研究表明，代谢重编程——包括葡萄糖、脂质和氨基酸代谢的改变——在这种疾病的发生和发展中都起着关键作用。为了更深入地了解这些代谢变化，科学家们越来越多地采用代谢组学，这是一种非侵入性技术，可检测和量化癌组织内的小分子，从而加强预后评估。
分析胃癌组织的代谢谱可揭示关键代谢途径的显著变化，这可能为靶向治疗开辟新途径，并最终改善患者预后。
本文综述了胃癌代谢重编程研究的最新进展，旨在确定潜在的治疗靶点并为患者带来新希望。
